Lv6
1840 积分 2023-04-17 加入
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial
2天前
已完结
The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
7天前
已完结
Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study
7天前
已完结
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
17天前
已完结
Liposomal vs conventional irinotecan: safety profiles compared
17天前
已完结
Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning
23天前
已完结
Exposure-Response Analysis of Guselkumab in the Maintenance Phase in Adults with Moderately to Severely Active Ulcerative Colitis
23天前
已关闭
BilT03: Phase 1b/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer
24天前
已完结
A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal nanoparticle-formulated and conventional anticancer irinotecan
24天前
已完结
皖公网安备34019202002308
